晚期上皮性卵巢癌术后顺铂腹腔灌注联合化疗疗效观

目的探讨顺铂（Cisplatin,DDP）腹腔灌注联合环磷酰胺（Cyclophosphamide,CTX）化疗治疗卵巢癌患者术后的疗效及预后因素。方法对2000年6月至2005年6月间入住我院的晚期卵巢癌患者术后43例进行回顾性分析,所有患者都经初次手术,化疗方案为PC（CTX iv＋DDP腹腔灌注）,分别为1-~12个疗程不等,分析他们的药物反应以及预后情况。结果Ⅲ期患者中CR10例,PR 14例,SD6例,PD1例,总有效率（overall response rate,ORR）为77.4%。Ⅳ期患者CR3例,PR5例,SD3例,PD1例,PR5例,SD3例,PD1例,ORR为66.7%,两组无显著差异。但Ⅲ期同Ⅳ期患者3年生存率及5年生存率均有显著性差异。43例无进展生存PFS（progression-free survival,PFS）为21.5个月,平均生存时间为37.5个月。结论顺铂腹腔灌注联合CTX化疗治疗卵巢癌是有效而且安全的,预后与病理类型、组织分级、术后残留癌大小及化疗疗程相关。

The efficacy and toxicities of cisplatin chemotherapy intraperitoneal infusion plus CTX in treatment of advanced epithelial ovarian cancer

OBJECTIVE To study the efficacy and toxicities of intraperitoneal infusion plus CTX in treatment of advanced epithelial ovarian cancer.METHODS Resrospective analysis was utilized to analyze the clinical materials of 43 cases of advanced epithelial ovarian cancer in our hospital from June 2000 to June 2005.They were all recerived cisplatin chemotherapy intraperitoneal infusion plus ctx each 3~4weeks,ranging from 1~12 cycles.Analysis their response and prgnosis.RESULTS Ⅲ CR10 cases of patients,PR 14 n,SD6 cases,PD1,the ORR was 77.4%.Ⅳ patients with CR3 cases,PR5 cases,SD3 cases,PD1 cases,PR5 cases,SD3 cases,PD1 cases,the ORR was 66.7%,no significant difference between the two groups.However,Ⅲ and Ⅳ of 3-year survival rate and 5-year survival rates were significantly different.43 patients,the PFS was 21.5 months,the average survival time was 37.5 months.CONCLUSION Cisplatin chemotherapy intraperitoneal infusion plus ctx chemotherapy in ovarian cancer is effective and safe.Prognosis is related with pathological type,histological grade,postoperative residual tumor size and chemotherapy treatment.